Loading...
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation
Dasatinib is a novel, potent, ATP-competitive inhibitor of Bcr-Abl, cKIT, and Src family kinases that exhibits efficacy in patients with imatinib-resistant chronic myelogenous leukemia. Dasatinib treatment is associated with mild thrombocytopenia and an increased risk of bleeding, but its biological...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3109542/ https://ncbi.nlm.nih.gov/pubmed/21385851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-12-326850 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|